RxDoctor Payments Data

Rachel Porter, APRN

Family · Andover, KSNPI 1386262707

Payments from drug & device makers

$3,223in general payments, 2019–2025

Across 224 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$610
  • Novo Nordisk$406
  • Lilly USA, LLC$388
  • AstraZeneca$248
  • Amgen$226
  • GSK$179
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,223100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,223 in reported general payments places this provider in the 90th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$18,112
Medicare patients
125
Services billed
424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban16$16,664
Soliqua 100-33Insulin Glargine/Lixisenatide13$9,112
Atorvastatin Calcium85$644
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$555
Metoprolol Succinate24$315
Ciprofloxacin Hcl17$257
Venlafaxine Hcl ErVenlafaxine Hcl21$252
Amlodipine Besylate56$232
Levothyroxine Sodium36$218
Losartan Potassium34$196
Cyclobenzaprine Hcl18$168
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$143
Sertraline Hcl15$139
Gabapentin14$129
Bupropion XlBupropion Hcl11$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$85$16,66416 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$89$9,11213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,579 family providers in Kansas.

Other family in Andover

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →